Evidence map›Paper›PMID 23028380›Full record

ArticlePLoS genetics2012

GWAS of diabetic nephropathy: is the GENIE out of the bottle?

Carsten A Böger, John R Sedor

Abstract readComment
In one paragraph

Article in PLoS genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. ErbB4 deletion predisposes to development of metabolic syndrome in mice.American journal of physiology. Endocrinology and metabolism · 2018
    Article
  5. Article
  6. ErbB4 deletion accelerates renal fibrosis following renal injury.American journal of physiology. Renal physiology · 2018
    Article
  7. Genome-wide association studies in pediatric chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2016
    Review
  8. Observational
  9. Article
  10. Observational
  11. The genetics of diabetic complications.Nature reviews. Nephrology · 2015
    Review
  12. Review
  13. Diabetic nephropathy: diagnosis and treatment.Nature reviews. Endocrinology · 2013
    Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Carsten A BögerDepartment of Internal Medicine II, Nephrology, University Medical Center Regensburg, Regensburg, Germany. carsten.boeger@klinik.uni-regensburg.de
John R Sedor

Funding

GENETIC REGULATION OF RENAL DISEASE PROGRESSIONU01DK057329 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI SEDOR, JOHN R. · 1999 to 2006
$2.3M
Kidney disease mechanisms associated with human genetic variationR01DK097836 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI BRUGGEMAN, LESLIE A, O'TOOLE, JOHN F. · 2014 to 2017
$2.0M
Renal Disease Progression in African AmericansR01DK059997 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI SCHELLING, JEFFREY R · 2002 to 2005
$1.5M
Kidney disease mechanisms associated with human genetic variationR56DK097836 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI BRUGGEMAN, LESLIE A, O'TOOLE, JOHN F. · 2012 to 2012
$198k
NIDDK NIH HHS DK057329NIDDK NIH HHS DK059997NIDDK NIH HHS DK097836NIDDK NIH HHS R01 DK059997NIDDK NIH HHS R01 DK097836NIDDK NIH HHS R56 DK097836NIDDK NIH HHS U01 DK057329
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Kidney Failure, ChronicDiabetes Mellitus, Type 1Diabetic NephropathiesErbB ReceptorsHumansNuclear ProteinsReceptor, ErbB-4AFF3 protein, humanERBB4 protein, humanErbB ReceptorsNuclear ProteinsReceptor, ErbB-4

Identifiers

PMID23028380
PMCPMC3447973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.